186 related articles for article (PubMed ID: 37828942)
21. Clinical Features and Microvascular Complications Risk Factors of Early-onset Type 2 Diabetes Mellitus.
Huang JX; Liao YF; Li YM
Curr Med Sci; 2019 Oct; 39(5):754-758. PubMed ID: 31612393
[TBL] [Abstract][Full Text] [Related]
22. GA/HbA1c ratio is a simple and practical indicator to evaluate the risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: an observational study.
Wang JW; Jin CH; Ke JF; Ma YL; Wang YJ; Lu JX; Li MF; Li LX
Diabetol Metab Syndr; 2022 Nov; 14(1):167. PubMed ID: 36369095
[TBL] [Abstract][Full Text] [Related]
23. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
24. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
[TBL] [Abstract][Full Text] [Related]
25. Monocyte to High-Density Lipoprotein Cholesterol Ratio at the Nexus of Type 2 Diabetes Mellitus Patients With Metabolic-Associated Fatty Liver Disease.
Jia J; Liu R; Wei W; Yu F; Yu X; Shen Y; Chen C; Cai Z; Wang C; Zhao Z; Wang D; Yang L; Yuan G
Front Physiol; 2021; 12():762242. PubMed ID: 34975521
[No Abstract] [Full Text] [Related]
26. Metabolic Syndrome in Type 2 Diabetes Mellitus Patients: Prevalence, Risk Factors, and Associated Microvascular Complications.
Asghar S; Asghar S; Shahid S; Fatima M; Bukhari SMH; Nadeem Siddiqui S
Cureus; 2023 May; 15(5):e39076. PubMed ID: 37323312
[TBL] [Abstract][Full Text] [Related]
27. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
[TBL] [Abstract][Full Text] [Related]
28. Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.
Ding Y; Deng Q; Yang M; Niu H; Wang Z; Xia S
Diabetes Metab Syndr Obes; 2023; 16():3303-3329. PubMed ID: 37905232
[TBL] [Abstract][Full Text] [Related]
29. Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus.
Gao Q; Feng L; Zhou W; Li X; Yin L; Wang Y
Diabetes Metab Syndr Obes; 2023; 16():2345-2354. PubMed ID: 37577041
[TBL] [Abstract][Full Text] [Related]
30. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
[TBL] [Abstract][Full Text] [Related]
31. The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD.
Pan B; Zhao Y; Chen C; Cai J; Li K; Wang Y; Liu J
Endocrine; 2024 Feb; ():. PubMed ID: 38367145
[TBL] [Abstract][Full Text] [Related]
32. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
[TBL] [Abstract][Full Text] [Related]
33. TOTAL BODY ADIPOSITY, TRIGLYCERIDES, AND LEG FAT ARE INDEPENDENT RISK FACTORS FOR DIABETIC PERIPHERAL NEUROPATHY IN CHINESE PATIENTS WITH TYPE 2 DIABETES MELLITUS.
Zhen Q; Yao N; Chen X; Zhang X; Wang Z; Ge Q
Endocr Pract; 2019 Mar; 25(3):270-278. PubMed ID: 30913011
[TBL] [Abstract][Full Text] [Related]
34. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
35. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
Ye J; Zhuang X; Li X; Gong X; Sun Y; Wang W; Feng S; Wu T; Zhong B
Metabolism; 2022 Nov; 136():155294. PubMed ID: 35995280
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
[TBL] [Abstract][Full Text] [Related]
37. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
[TBL] [Abstract][Full Text] [Related]
38. Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD).
Shao L; Liu J; Song Y; Yang W; Gong L; Lyu Z; Zhu Q; Fu J; Li J; Shi J
Clin Chim Acta; 2023 Jan; 538():203-210. PubMed ID: 36549641
[TBL] [Abstract][Full Text] [Related]
39. Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis.
Wanderley Rocha DR; Jorge AR; Braulio VB; Arbex AK; Marcadenti A
Curr Diabetes Rev; 2017; 13(1):11-18. PubMed ID: 26467189
[TBL] [Abstract][Full Text] [Related]
40. The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults.
Taheri E; Pourhoseingholi MA; Moslem A; Hassani AH; Mousavi Jarrahi A; Asadzadeh Aghdaei H; Zali MR; Hatami B
J Diabetes Metab Disord; 2022 Jun; 21(1):97-107. PubMed ID: 35673435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
